News & Views

October 14, 2024

Disclosure of Clinical Trials – APM Health Interview with Ali Pashazadeh, Treehill Partners CEO

Posted By: TreehillPartners
In: Drug Development

Introducing a mechanism for patenting a new potential use for a drug technology for a period of time after publishing clinical trial data...

November 20, 2025

London Life Sciences Week – In-Depth Interview

Posted By: TreehillPartners
In: Drug Development

November 19, 2025

Manufacturing Flexibility

Posted By: TreehillPartners
In: Drug Development, Strategy & Corporate Development

November 3, 2025

Pharma’s Path Through Industry Turbulence

Posted By: TreehillPartners
In: Drug Development, Leadership & Restructuring

October 23, 2025

Neurology M&A – Treehill Quotes in Endpoints News

Posted By: TreehillPartners
In: Dealmaking

October 1, 2025

Treehill Partners CEO Featured in Newsweek Coverage of TrumpRx Initiative

Posted By: TreehillPartners
In: Drug Development, Strategy & Corporate Development

October 1, 2024

European Immunology M&A Flares Up As Big Pharma Seeks Next Blockbuster – Ali Pashazadeh, Treehill’s CEO gives key insights for article in Mergermarket’s Snapshot series.

Posted By: TreehillPartners
In: Dealmaking

Ali Pashazadeh, Treehill’s CEO, contributes to an article in Mergermarket summarising current trends in the European immunology, inflammatory and autoimmune marketplaces...

September 30, 2025

Treehill Partners Experts Featured in FirstWord Report on Biomarkers in Rare Disease Therapies

Posted By: TreehillPartners
In: Drug Development, Leadership & Restructuring, Strategy & Corporate Development

September 11, 2025

Keep the Patients in Mind

Posted By: TreehillPartners
In: Leadership & Restructuring

September 5, 2025

Navigating Biotech’s Perfect Storm: Pharmaphorum Podcast

Posted By: TreehillPartners
In: Leadership & Restructuring, Strategy & Corporate Development

August 22, 2025

Optimizing Biomanufacturing

Posted By: TreehillPartners
In: Drug Development

August 16, 2025

The Biotech Funding Model Needs a Major Overhaul

Posted By: TreehillPartners
In: Drug Development, Strategy & Corporate Development

September 30, 2024

Biotech Course Correction – BioProcess Online podcast with Treehill Partners CEO Ali Pashazadeh

Posted By: TreehillPartners
In: Leadership & Restructuring, Strategy & Corporate Development

It wouldn't be accurate to say that surgeon-turned-healthcare investment banker and consultant Dr. Ali Pashazadeh traded his scalpels for spreadsheets...

July 24, 2025

When VC Steps Back: Finding Alternative Biotech Funding

Posted By: TreehillPartners
In: Financing & Capital Markets, Strategy & Corporate Development

July 21, 2025

“We’re making the same mistakes over and over”

Posted By: TreehillPartners
In: Did you know?, Drug Development

July 21, 2025

Can Europe take the lead on biotech?

Posted By: TreehillPartners
In: Did you know?

July 14, 2025

China Biotech’s Stunning Advance Is Changing the World’s Drug Pipeline

Posted By: TreehillPartners
In: Business Development & Licensing, Drug Development, Leadership & Restructuring, Strategy & Corporate Development

Chinese biotech's advance has been as ferocious as the nation's breakthrough efforts in AI and EVs, eclipsing the EU and catching up to the US...

July 14, 2025

Unfundable Gaps – Treehill CEO quoted in BioSpace

Posted By: TreehillPartners
In: Strategy & Corporate Development

Companies are being asked to take-on increasingly complex challenges in an environment where there are diminished resources...

August 30, 2024

Long-term perspectives on new drug classes – Ali Pashazadeh, Treehill Partners CEO, quoted in Endpoints News

Posted By: TreehillPartners
In: Drug Development

Using a mechanistic pathway or agent to achieve something else than it was designed to do, leaves questions unanswered that will become clear only over time...

June 25, 2025

“I wish you’d called us before you’d run that Phase II” – Ali Pashazadeh, Treehill Partners CEO, in Scrip Interview

Posted By: TreehillPartners
In: Dealmaking, Drug Development, Leadership & Restructuring, Strategy & Corporate Development

Mandy Jackson, US editor of Citeline's Scrip, has published the below interview with Ali Pashazadeh, Treehill Partners CEO...

June 20, 2025

From Molecule to Market – BioSpectrum Asia interview with Ali Pashazadeh, Treehill Partners CEO

Posted By: TreehillPartners
In: Uncategorized

At this year's BIO Convention in Boston, Ali Pashazadeh, Treehill Partners CEO, spoke with Manasee Kurlekar, BioSpectrum Asia Chief Executive Officer...

June 10, 2025

We need to both Do the Right Thing and Do It the Right Way

Posted By: TreehillPartners
In: Drug Development, Strategy & Corporate Development

June 9, 2025

Biotech, Pharma, Outsourcing & Capital – Podium Discussion at PCMG Annual Assembly

Posted By: TreehillPartners
In: Drug Development, Strategy & Corporate Development

At PCMG Clinical Outsourcing Community today, Ali Pashazadeh, Treehill Partners CEO, was giving a podium presentation on "A view from the top - how will Clinical Development Outsourcing adapt to a rapidly changing landscape"...

June 3, 2025

Tariffs On Toys … And API? Biopharma As The Next Battleground – Outsourced Pharma Interview with Treehill Partners CEO, Ali Pashazadeh

Posted By: TreehillPartners
In: Drug Development

Whilst outsourcing of drug development and manufacturing is an attempt to undertake purposeful action in a web of interdependent contingencies, this interview with Ali Pashazadeh, Treehill Partners CEO...

July 19, 2024

Too Much Data: a Burden or a Blessing? – Clinical Trials Arena Article Quote

Posted By: TreehillPartners
In: Drug Development

May 22, 2025

Evolve Or Fade Away? Biotech’s Outsourcing Moment – Outsourced Pharma interview with Ali Pashazadeh, Treehill Partners CEO

Posted By: TreehillPartners
In: Leadership & Restructuring

Outsourced Pharma Chief Editor Louis Garguilo has interviewed Ali Pashazadeh, Treehill Partners CEO, to help think through the evolving U.S. policies and tariff turbulance as they relate to the outsourcing of development and manufacturing...

May 22, 2025

Treehill Partners in Pink Sheet’s “Quotable: Top Experts On Policy Hot Topics”

Posted By: TreehillPartners
In: Drug Development, Strategy & Corporate Development

The Pink Sheet and Citeline have just published their summary article 'Quotable: Top Experts on Policy Hot Topics’, picking out 12 recent articles that are ‘must read’....

May 2, 2025

Opportunities & Challenges in the Evolving Regulatory Landscape in Europe – Pink Sheet Interview with Mark Mayhew, Treehill Partners

Posted By: TreehillPartners
In: Drug Development

Pink Sheet, the Citeline regulatory publication, reporter Eliza Slawther has interviewed Mark Mayhew, Treehill Partners...

May 1, 2025

Filling the NIH Funding Gap to Protect Biopharma Research – BioWorld

Posted By: TreehillPartners
In: Drug Development, Financing & Capital Markets

Following an interview with BioWorld (top 10 life science publication founded 1991) managing editor Karen Carey, the article recites Ali Pashazadeh, Treehill Partners CEO...

April 24, 2025

Navigating CGT Biotech’s Financial Headwinds And The Path Forward – Cell & Gene Interview with Ali Pashazadeh, Treehill Partners CEO

Posted By: TreehillPartners
In: Drug Development, Leadership & Restructuring

Subscribe to our mailings!

The Biotech Funding Model Needs a Major Overhaul

TLDR Biotech interview with Ali Pashazadeh, Treehill Partners CEO The “worst investment drought in recent history” is real. Whilst private biotech companies remain in the

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.